NEIL3 Deficiency Enhances HCC Cell Sensitivity to Oxaliplatin by Inhibiting the Fanconi Anaemia Pathway
Cell Biology International · 2025
DOI: 10.1002/cbin.70023 ↗At a glance
Journal article in Cell Biology International, 2025. Written by Jialiang Wang and 6 co-authors. Institution: Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Major MEDLINE topics: Oxaliplatin, Carcinoma, Hepatocellular, Liver Neoplasms, N-Glycosyl Hydrolases. 45 references. Funded by: This study was supported by the General Planned Project of Guangzhou Science and Technology (grant number 202102010195)..
Abstract (original language)
Despite some achievements in oxaliplatin‐based chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC), the abnormal activation of DNA damage repair pathways in HCC cells remains a major problem, limiting the efficacy of oxaliplatin‐based chemotherapy. In a previous study, we found that endonuclease VIII‐like protein 3 (NEIL3) is expressed in a high proportion of patients with HCC and associated with an unfavourable prognosis. However, the role of NEIL3 in chemoresistance is still unclear. The aim of this study was to evaluate whether and how NEIL3 regulates oxaliplatin anti‐tumour efficacy. Gene expression after oxaliplatin treatment in HCC cell lines was assessed by real‐time quantitative PCR, western blot analysis and bioinformatics analysis. The effect of NEIL3 on regulating oxaliplatin efficacy was assessed using cell counting kit‐8 assays, colony formation assays, flow cytometry and an in vivo nude mice study. Mechanistic insights into the sensitivity to oxaliplatin mediated by the inhibition of NEIL3 were obtained through immunofluorescence and RNA sequencing analyses. Our findings demonstrated that NEIL3 expression was markedly downregulated after oxaliplatin administration. NEIL3 knockdown impaired cell viability and colony formation and increased apoptosis in HCC cells exposed to oxaliplatin. In addition, NEIL3 inhibition reduced tumour progression and enhanced oxaliplatin efficacy in xenograft nude mice models. Furthermore, knocking down NEIL3 significantly increased the oxaliplatin‐mediated inhibition of the Fanconi anaemia pathway. Our results revealed that NEIL3 may be a promising therapeutic target for improving oxaliplatin efficacy in the treatment of HCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
ORCID profiles: Lin Gu, Xiaoyan Li, Lubiao Chen
Funding
- This study was supported by the General Planned Project of Guangzhou Science and Technology (grant number 202102010195).
Cite
APA
Wang, J., Liao, C., Luo, J., Li, M., Gu, L., Li, X., & Chen, L. (2025). NEIL3 Deficiency Enhances HCC Cell Sensitivity to Oxaliplatin by Inhibiting the Fanconi Anaemia Pathway. Cell Biology International. https://doi.org/10.1002/cbin.70023
Vancouver
Wang J, Liao C, Luo J, Li M, Gu L, Li X, et al. NEIL3 Deficiency Enhances HCC Cell Sensitivity to Oxaliplatin by Inhibiting the Fanconi Anaemia Pathway. Cell Biology International. 2025. doi:10.1002/cbin.70023
BibTeX
@article{Wang2025,
author = {Wang, Jialiang and Liao, Chunhong and Luo, Jing and Li, Mingna and Gu, Lin and Li, Xiaoyan and Chen, Lubiao},
title = {NEIL3 Deficiency Enhances HCC Cell Sensitivity to Oxaliplatin by Inhibiting the Fanconi Anaemia Pathway},
journal = {Cell Biology International},
year = {2025},
doi = {10.1002/cbin.70023}
}
EUVIMED